Stock Review for Biotech's Investors -- Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics

NEW YORK, March 23, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on CNCE, CTRV, CRBP, and CORT which can be accessed for free by signing up to www.wallstequities.com/registration. On Thursday, March 22, 2018, the NASDAQ Composite ended the trading session at 7,166.68, down 2.43%; the Dow Jones Industrial Average edged 2.93% lower, to finish at 23,957.89; and the S&P 500 closed at 2,643.69, dropping 2.52%. Losses were broad based as eight out of nine sectors ended the day in negative. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Concert Pharmaceuticals Inc. (NASDAQ: CNCE), ContraVir Pharmaceuticals Inc. (NASDAQ: CTRV), Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), and Corcept Therapeutics Inc. (NASDAQ: CORT). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Concert Pharmaceuticals

Lexington, Massachusetts headquartered Concert Pharmaceuticals Inc.'s stock finished Thursday's session 1.02% higher at $23.84 with a total trading volume of 236,850 shares. The Company's shares have advanced 11.35% in the last month and 29.35% over the past twelve months. The stock is trading above its 50-day and 200-day moving average by 9.98% and 30.14%, respectively. Additionally, shares of Concert Pharma, which operates as a clinical stage biopharmaceutical company, have a Relative Strength Index (RSI) of 64.43.

On March 09th, 2018, research firm Mizuho upgraded the Company's stock rating from 'Neutral' to 'Buy' while revising its previous target price from $23 a share to $27 a share. Get the full research report on CNCE for free by clicking below at:

www.wallstequities.com/registration/?symbol=CNCE

ContraVir Pharmaceuticals

On Thursday, shares in Edison, New Jersey headquartered ContraVir Pharmaceuticals Inc. recorded a trading volume of 890,149 shares. The stock ended the session 3.84% higher at $0.25. The Company's shares have advanced 1.94% in the last month. The stock is trading below its 50-day moving average by 7.57%. Moreover, shares of ContraVir Pharma, which focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus infections, have an RSI of 48.78. Get access to our top-rated research, including the free report on CTRV at:

www.wallstequities.com/registration/?symbol=CTRV

Corbus Pharmaceuticals Holdings

Norwood, Massachusetts-based Corbus Pharmaceuticals Holdings Inc.'s shares closed the day 4.29% lower at $6.70. The stock recorded a trading volume of 493,073 shares. The stock is trading below its 50-day moving average by 11.62%. Additionally, shares of Corbus Pharma, which focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases, have an RSI of 36.74. Click here to subscribe for a free membership which welcomes you with our report on CRBP at:

www.wallstequities.com/registration/?symbol=CRBP

Corcept Therapeutics

Shares in Menlo Park, California headquartered Corcept Therapeutics Inc. finished 3.91% lower at $16.94. The stock recorded a trading volume of 1.27 million shares. The Company's shares have 69.99% over the last twelve months. The stock is trading above its 200-day moving average by 1.69%. Furthermore, shares of Corcept Therapeutics, which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 43.29.

On March 09th, 2018, research firm B. Riley FBR, Inc. initiated a 'Buy' rating on the Company's stock, with a target price of $30 per share. Join our big investor community at Wall St. Equities today and get your free report on CORT at:

www.wallstequities.com/registration/?symbol=CORT

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: +21-32-044-483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----concert-pharma-contravir-pharma-corbus-pharma-and-corcept-therapeutics-300618641.html

SOURCE Wall St. Equities

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.